Axway Named a Leader in New API Management Software Report
Axway (Euronext: AXW.PA), a leading provider of API management and integration software, is proud to announce that it has been positioned as a Leader in The Forrester Wave™: API Management Software, Q3 2024, published on July 1, 2024.¹
"We are always honored when our customers share the positive experiences and outcomes they have had with Axway," said Vince Padua, Chief Product Officer at Axway. "We're invested in their success, providing the expertise and guidance needed to treat APIs as strategic business products.”
Axway was one of 15 select companies that Forrester invited to participate in its evaluation, The Forrester Wave™: API Management Software, Q3 2024. In this evaluation of its Amplify API Management, Axway earned the highest scores possible in seven evaluation criteria, including federated gateway management, API product management, and adoption.
“This recognition validates for us our unique API business strategy program, which is just one example of how we go above and beyond to ensure you extract maximum value from API investments. We empower organizations with universal API management tools that break down barriers and provide a single source of truth for the entire API landscape,” said Padua.
The report notes: “Axway focuses on digital business that is multicloud, multiprotocol, and multigateway. Its roadmap seeks to deliver a more unified product line, non-REST protocol enhancements, more gateway federation, AI for API creation and consumption, and gateway modernization... It is the only vendor in this evaluation to provide robust support for third-party federated gateways...” ¹
“The Amplify platform lets you discover, use, and govern APIs across multiple gateways, vendors, and environments, simplifying adoption and use of APIs. But providing an industry-leading API management solution isn’t enough,” adds Padua. “Just as essential is accompanying our customers in designing an API management strategy that will drive the best results from a company’s investment.”
According to the report, “Reference customers say Axway is a supportive partner that listens to its customers. They also love its support for third-party gateways.” ¹
With Amplify API Management, the global manufacturing and engineering innovator Bosch was able to accelerate product and service innovation.
“We manage over 2,000 APIs using Amplify API Management, with a volume of several hundred million transactions per month. These APIs enable a wide range of use cases, from connecting SAP S/4HANA with other line-of-business solutions to supporting smart heating systems for office buildings,” said David Geiger, Head of API Management at Bosch Digital.
“And with Amplify Marketplace, developers can easily find the right APIs without traversing the entire organization; this saves a huge amount of time.”
Baird, an investment bank and financial services company, drove rapid adoption with a central API catalog and secure self-service consumption with Axway.
“Today, our developers can see all the APIs their peers have developed, identify any application dependences, and check the source repository to see who last worked on it,” said Jim Cornelius, SVP, IT Architect at Baird. “With a central view of which APIs are available, our teams can leverage already-existing code or even an entire API created by another team to accelerate their own development work. Without a doubt, this capability is reducing duplication of effort in our development process — helping us to minimize our time to market for new data-driven services.”
Click here to view a complimentary copy of The Forrester Wave™ report.
¹The Forrester Wave™: API Management Software, Q3 2024, Forrester Research, Inc., July 1, 2024
About Axway
Axway is an independent technology provider that sustainably grows enduring value for our customers based on a history of trust, security, and stability that goes back nearly 25 years. Our extensive portfolio, which encompasses Managed File Transfer, B2B Integration, Financial Accounting Hub, and comprehensive API management through Amplify, empowers organizations to seamlessly integrate their internal and external ecosystems and succeed in a shifting digital business landscape. Learn more at axway.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701226257/en/
Contacts
Media
Todd Holbrook
Tel. (480) 371-0113
tholbrook@axway.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom